ExaGrid Announces Its Largest Scale-Out System to Date, Doubling Full Backup Capacity and Ingest Speed
ExaGrid®, a leading provider of hyper-converged secondary storage for backup, announced its largest, most powerful appliance in its arsenal of backup storage with data deduplication – the EX63000E.
The EX63000E appliance has 58% more capacity than its predecessor, allowing for a 63TB full backup. Leveraging the strength of ExaGrid’s scale-out technology, up to thirty-two (32) EX63000E appliances can be combined in a single scale-out system [an increase from twenty-five (25) combined appliances previously], allowing for a 2PB full backup, which is a 100% increase over the previous 1PB. The EX63000E has a maximum ingest rate of 13.5TB/hr. per appliance, so when thirty-two (32) EX63000Es are combined in a single system, the maximum ingest rate is 432TB/hr.
The Dell EMC DD9800 has a maximum full backup capacity of 1PB at 68TB/hr. with DD Boost. Two stand-alone Data Domain systems would be required for a 2PB full backup and would still only perform at a combined ingest rate of 136TB/hr., which is one-third that of ExaGrid. Compared to Data Domain, ExaGrid can scale to 2X the full backup capacity, over 3X the ingest rate, and – with ExaGrid’s unique landing zone – over 20X the restore performance.
“The introduction of the EX63000E with scalability to a 2PB single system is ground-breaking,” said ExaGrid’s president and CEO, Bill Andrews. “As enterprise IT data centers struggle to keep pace with data growth, our newest system doubles the headroom of our previous system – and that of our closest competitor. We pride ourselves on being customer-centric by developing and bringing to market what the IT customer truly needs.
“Many backup systems simply add inline data deduplication into a scale-up primary storage system. The first generation of inline/scale-up appliances do save backup storage; however, they break on every other level, including ingest, restore, and scalability. The alternative of performing data deduplication in the backup software uses even more disk and is much slower than the first generation inline/scale-up appliances. Only ExaGrid provides aggressive backup storage efficiency, scale-out for scalability, and also fixes all of the compute challenges of data deduplication, resulting in the fastest backups and fastest restores.”
All other solutions - whether dedicated appliances or deduplication in the backup software - slow down backups by attempting to deduplicate the data during the backup window, which is extremely slow. In addition, they only store deduplicated data that requires data rehydration for every request, delaying restores by hours to days. Alternatively, ExaGrid employs a combination of Zone Level Deduplication, a unique Landing Zone, Adaptive Deduplication, and Scale-out Architecture to not only store the least amount of deduplicated data, but also to provide backup/restore performance and scalability that is unmatched in the industry.
ExaGrid’s ingest is 3X faster - and restores/VM boots are up to 20X faster - than its closest competitor. In addition, since each ExaGrid appliance that is added to an existing system brings compute with capacity, the backup window remains fixed in length even as data increases. ExaGrid not only delivers the fastest backups and restores, but is the only solution that truly scales, provides a fixed length backup window as data grows, and eliminates forklift upgrades as well as product obsolescence.
Because of its unique landing zone and scale-out architecture, ExaGrid is the only backup storage solution for Veeam that allows for long-term deduplicated retention while also preserving the Veeam value proposition of VM boots in seconds to minutes.
ExaGrid lowers cost and improves performance and scalability over Dell EMC Data Domain, HP StoreOnce, Veritas Backup Appliance for NetBackup, Commvault deduplication to straight disk, Commvault backup appliances and many other disk backup solutions.
ExaGrid’s published customer success stories and enterprise stories number over 350, more than all other vendors in the space combined. These include a two-page narrative and customer quote, demonstrating how satisfied customers are with ExaGrid’s unique architectural approach, differentiated product, and unrivalled customer support. Customers consistently state that not only is the product best-in-class, but ‘it just works.’ “This demonstrates how satisfied ExaGrid customers are with our architectural approach, product, and customer support,” said Andrews.
ExaGrid provides hyper-converged secondary storage for backup with data deduplication, a unique landing zone, and scale-out architecture. ExaGrid’s landing zone provides for the fastest backups, restores, and instant VM recoveries. Its scale-out architecture includes full appliances in a scale-out system and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades. Visit us at www.exagrid.com or connect with us on LinkedIn. See what our customers have to say about their own ExaGrid experiences and why they now spend significantly less time on backup.
ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.
Christine Murphy, 508-898-2872 x248
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Ultra-Low Power Lattice sensAI Leads Mass Market Enablement of Artificial Intelligence in Edge Devices21.5.2018 12:00 | Pressemelding
Lattice Semiconductor Corporation (NASDAQ: LSCC) today unveiled Lattice sensAI™ – a complete technology stack combining modular hardware kits, neural network IP cores, software tools, reference designs and custom design services – to accelerate integration of machine learning inferencing into broad market IoT applications. With solutions optimized for ultra-low power consumption (under 1 mW–1 W), small package size (5.5 mm2 –100 mm2), interface flexibility (MIPI® CSI-2, LVDS, GigE, etc.), and high-volume pricing (~$1-$10 USD), Lattice sensAI stack fast-tracks implementation of edge computing close to the source of data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005011/en/ (Graphic: Business Wire) “Lattice sensAI addresses the unmet need for flexible, low cost, ultra-low power AI silicon solutions suited for rapid deployment across a wide range of emerging, mass market IoT applications,” said Deepak Boppana, senior
NioCorp Awards Contract to Rockwell Automation on Groundbreaking Critical Minerals, Mining and Processing Facility in Nebraska21.5.2018 12:00 | Pressemelding
NioCorp Developments Ltd. (TSX: NB, OTCQX: NIOBF), a developer of superalloy metals, has awarded a major contract to Rockwell Automation (NYSE: ROK) to engineer, design and procure process automation and instrumentation for NioCorp’s proposed critical minerals, mining and processing facility in Elk Creek, Nebraska. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005228/en/ Three superalloy metals – niobium, scandium and titanium – are expected to be produced by the facility as early as 2021. These critical materials are used in the aerospace, defense, automotive, clean energy, commercial aviation and mega-infrastructure sectors. Generally, these superalloys enable increased strength and lighter weight in transportation and other systems, leading to better fuel efficiency and lower greenhouse gas and other air emissions, according to NioCorp. “We selected Rockwell Automation and its partners to automate our process equip
Biosimilars could facilitate early access to life changing biological treatments for patients says Celltrion Healthcare21.5.2018 11:27 | Pressemelding
At the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting in Baltimore, Celltrion Healthcare today advocated for healthcare systems to introduce biologics earlier in a patient’s treatment regimen in order to improve clinical outcomes. Several studies show that the early introduction of biologics can bring greater clinical benefit to patients.1,2,3,4,5,6 However, only a limited number of patients have access to biological treatment due to the high-cost of biologics and current reimbursement policies determined by pharmacoeconomic evaluations. Since the introduction of biosimilars, the overall cost of biological treatments has reduced in Europe, allowing an increased number of patients to access this important treatment option earlier in their course of treatment.7 Professor Jørgen Jahnsen said, “For the treatment of inflammatory bowel disease, biological treatments are proven to be the most efficacious medical therapy and their ea
Dole’s Joint Venture Recycling Company Celebrates 25 Years21.5.2018 11:00 | Pressemelding
Dole Food Company announced today that Recyplast S.A., an innovative plastic recycling company based in Costa Rica and with joint ownership including a subsidiary of Dole Fresh Fruit, recently surpassed 25 years in its mission to dramatically reduce and reuse agricultural waste. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005160/en/ Raul Martinez (right), General Manager of Dole Standard Fruit de Costa Rica, receives a plaque from Jose Miguel Ramirez, General Manager of Recyplast, in recognition of the contribution of Dole's banana plantations in the correct handling, storage, and provision of field plastic waste. The plastic recycling facility pioneered the collection of field plastics after use in banana growing operations in Costa Rica. This reuse and recycling process includes reclamation of plastic bags that protect bananas from weather and insects, as well as the collection of plastic twine used to prop the ba
ViiV Healthcare Receives EU Marketing Authorisation for Juluca (dolutegravir/rilpivirine), the First 2-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV21.5.2018 10:11 | Pressemelding
ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Commission has granted marketing authorisation for Juluca (dolutegravir 50mg/rilpivirine 25mg) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.1 Juluca is a 2-drug regimen of dolutegravir (ViiV Healthcare), the most widely prescribed integrase inhibitor worldwide,2 and rilpivirine (Janssen Sciences Ireland UC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson).1 Deborah Waterhouse, CEO ViiV Healthcare said, “The European Commission Decision for Juluca is very positive news for people living with
Janssen Announces European Commission Approval of JULUCA®▼ (dolutegravir/rilpivirine), the First Two-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV-121.5.2018 10:06 | Pressemelding
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission has granted marketing authorisation for JULUCA® (dolutegravir 50mg [ViiV Healthcare]/rilpivirine 25mg [Janssen Sciences Ireland UC]).1 ViiV Healthcare, as the marketing authorisation holder, will market dolutegravir/rilpivirine in all countries in the European Union and European Economic Area. Dolutegravir/rilpivirine is the first two-drug regimen, once-daily, single-pill for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase inhibitor (INI).1 “The European Commission Decision for dolutegravir/rilpivirine marks a significant milestone in our 25-year commitment to make HIV history,” said Brian Woo